Drug recall · March 8, 2023
Carbidopa and Levodopa Tablets recall
Why: Packaging defect: observed packaging defect, blister packaging inadequately sealed.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Carbidopa and Levodopa Tablets, USP 25 mg/100 mg, 10x10 Unit Dose carton, Rx Only, Manufactured in Czech Republic by: Teva Czech Industries, s.r.o. Opava-Komarov, Czech Republic, Manufactured for: Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, Packaged and Distributed by: Major Pharmaceuticals Indianapolis, IN 46268 USA. NDC 0904-7257-61, UPC 3 09047 25761 4
- Lots / codes
Lot: M04145 Exp. 01/2024
- Quantity
- 17,586 cartons
- Company
- The Harvard Drug Group, La Vergne, TN
- Distribution
- Distributed Nationwide in the USA
- Initiated
- February 23, 2023 · Voluntary: Firm initiated
- Classified
- March 2, 2023
- Reported
- March 8, 2023
- Ended
- April 30, 2024
- How notified
- N/A
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Carbidopa
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.